Manufacturer Activity Reporting
The Manufacturer Activity Report accompanies each price increase report. Every drug that has either lost patent exclusivity or has received U.S. Food and Drug Administration approval in the last three calendar years is documented in the Manufacturer Activity Report. Pharmaceutical manufacturers also are required to report their aggregate, company-level research and development (R&D) costs for the most recent year for which final audit data is available.
This report is due within 30 days of the effective date of a price increase. Consult the User Guide for instructions.